Inter-vendor standardisation and quality assurance of quantitative cardiovascular magnetic resonance (CMR) T1-mapping for clinical practice and trials

用于临床实践和试验的定量心血管磁共振 (CMR) T1 映射的供应商间标准化和质量保证

• 批准号: 2884156
• 金额: --
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2884156
• 关键词: Inter; vendor; standardisation; quality; assurance

Quantitative CMR (qCMR) T1-mapping is named one of the most innovative technologies to evaluate heart disease by the European Society of Cardiology. T1-mapping provides pixel-wise characterisation of body tissue, beyond what conventional MRI offers, and has been shown to detect subclinical cardiac and liver disease. Each tissue type has a normal T1 range, deviation from which may indicate disease. However, there are many T1- mapping techniques, each with their own normal range on different scanners by different vendors. This lack of standardisation limits inter-centre comparability and wider roll-out for clinical use. We have successfully developed a cardiac T1-mapping technique - the Shortened Modified Look-Locker inversion recovery (ShMOLLI) - now in 5 international guidelines, with >60 papers, ~6000 citations and 5 awards. It has the largest clinical evidence base for any single T1-mapping method, and is the designated T1-mapping technique in UK Biobank (100,000 datasets by 2021/2022). We have also recently published our unique approach to mapping standardisation for clinical trials (2021), and had garnered support letters from 4 industry partners (GE included), with >100 interested CMR sites worldwide. Our method currently operates on a single vendor platform (Siemens), but now ready for inter-vendor standardisation. Given substantial inter-vendor differences in technologies, achieving this is an ambitious feat; this requires significant buy-in and investment from industry partners, to provide vendor-specific method implementation on vendor proprietary systems. Upon solving this unmet clinical need, we expect to translate qCMR mapping into widespread use in the NHS, through the use of common norms and guidelines. This would also allow the building of a vendor-independent national imaging database, compatible with UK Biobank, to address important clinical questions through big data and artificial intelligence. This study will rely on recently purchased GE MR scanner as a platform to enable inter-vendor standardisation programme. This proposed project is aligned to MRC's remit in several areas: the translational impact of diagnostic and data analytics, to enable a future national imaging database that is aligned with the UK Biobank big data, for further applications of artificial intelligence and machine learning, towards precision medicine. The project hinges on interdisciplinary skills and ways of working, between biomedical imaging, MR physics, physicians and industry partners, and will enable researcher mobility between sectors of health and the physical sciences.

定量CMR (qCMR) t1制图被欧洲心脏病学会评为评估心脏病最具创新性的技术之一。t1制图提供了超越传统MRI所能提供的身体组织的像素级特征，并已被证明可以检测亚临床心脏和肝脏疾病。每种组织类型都有正常的T1范围，偏离该范围可能预示着疾病。然而，有许多T1-映射技术，每一个都有自己的正常范围在不同的扫描仪上由不同的供应商。这种标准化的缺乏限制了中心间的可比性和临床应用的更广泛推广。我们已经成功开发了一种心脏t1映射技术——缩短修改Look-Locker反演恢复（ShMOLLI），目前在5个国际指南中，有60篇论文，6000次引用和5个奖项。它拥有任何单一t1制图方法的最大临床证据基础，并且是英国生物银行指定的t1制图技术（到2021/2022年将有100,000个数据集）。我们最近还发布了我们独特的临床试验测绘标准化方法（2021年），并获得了4个行业合作伙伴（包括GE）的支持信，全球有100个感兴趣的CMR站点。我们的方法目前在单个供应商平台（Siemens）上运行，但现在已经准备好进行供应商间的标准化。考虑到供应商之间在技术上的巨大差异，实现这一目标是一项雄心勃勃的壮举；这需要来自行业合作伙伴的大量购买和投资，以便在供应商专有系统上提供特定于供应商的方法实现。在解决这一未满足的临床需求后，我们希望通过使用共同的规范和指南，将qCMR映射转化为在NHS中广泛使用。这也将允许建立一个独立于供应商的国家成像数据库，与英国生物银行兼容，通过大数据和人工智能解决重要的临床问题。这项研究将依赖于最近购买的GE MR扫描仪作为平台，以实现供应商之间的标准化计划。这个拟议的项目与MRC在几个领域的职权范围一致：诊断和数据分析的转化影响，使未来的国家成像数据库与英国生物银行大数据保持一致，进一步应用人工智能和机器学习，走向精准医学。该项目取决于生物医学成像、核磁共振物理学、医生和行业合作伙伴之间的跨学科技能和工作方式，并将使研究人员能够在卫生和物理科学部门之间流动。